trending Market Intelligence /marketintelligence/en/news-insights/trending/50fFvdZbKGJ5ECk_0mrSiQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

FTC requires divestitures for Boehringer, Sanofi asset swap deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


FTC requires divestitures for Boehringer, Sanofi asset swap deal

Boehringer Ingelheim has agreed to divest certain animal health products in the U.S. to settle the U.S. Federal Trade Commission's complaint that the company's asset swap deal with Sanofi might be harmful for competition.

The proposed asset swap transaction entails the acquisition of Sanofi's animal care subsidiary Merial, valued at $13.53 billion, by the German pharmaceutical company, with Sanofi acquiring Boehringer's consumer healthcare business unit, valued at $7.98 billion, along with cash compensation from Boehringer of $5.54 billion.

Boehringer Ingelheim's consumer healthcare business in China would be excluded from the transaction.

In a complaint, the FTC alleged that the asset swap would have anticompetitive effects in the U.S. markets for various vaccines for companion animals and certain parasite control products for cattle and sheep. The complaint also states that the deal could result in higher prices and reduced service in these markets, and might raise the chances of coordinated interaction between competitors.

The FTC's proposed consent order seeks to preserve competition by requiring Boehringer Ingelheim to divest the companion animal vaccines to Eli Lilly & Co. and the company's Elanco Animal Health division and the parasite control products to Bayer AG.

Boehringer and Sanofi plan to close the potential transaction in the fourth quarter, subject to appropriate regulatory approvals. Sanofi plans to use part of the net proceeds of the transaction to repurchase shares.